Number of the records: 1  

Human multipotent mesenchymal stromal cells in the treatment of postoperative temporal bone defect: an animal model

  1. 1.
    SYSNO ASEP0450151
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleHuman multipotent mesenchymal stromal cells in the treatment of postoperative temporal bone defect: an animal model
    Author(s) Školoudík, L. (CZ)
    Chrobok, V. (CZ)
    Kalfert, D. (CZ)
    Kočí, Zuzana (UEM-P)
    Syková, Eva (UEM-P) RID
    Chumak, Tetyana (UEM-P)
    Popelář, Jiří (UEM-P) RID
    Syka, Josef (UEM-P) RID
    Laco, J. (CZ)
    Dědková, J. (CZ)
    Dayanithi, Govindan (UEM-P) RID
    Filip, S. (CZ)
    Number of authors12
    Source TitleCell Transplantation. - : Sage - ISSN 0963-6897
    Roč. 25, č. 7 (2016), s. 1405-1414
    Number of pages28 s.
    Languageeng - English
    CountryUS - United States
    KeywordsHuman bone marrow ; Human mesenchymal stromal cells (hMSCs) ; Middle ear surgery ; Temporal bone
    Subject RIVFP - Other Medical Disciplines
    R&D ProjectsLO1309 GA MŠMT - Ministry of Education, Youth and Sports (MEYS)
    Institutional supportUEM-P - RVO:68378041
    UT WOS000384801200017
    EID SCOPUS84978134221
    DOI10.3727/096368915X689730
    AnnotationCanal wall down mastoidectomy is one of the most effective treatments for cholesteatoma. However, it results in anatomical changes in the external and middle ear with a negative impact on the patient's quality of life. To provide complete closure of the mastoid cavity and normalize the anatomy of the middle and external ear, we used human multipotent mesenchymal stromal cells (hMSCs), GMP grade, in a guinea pig model. A method for preparing a biomaterial composed of hMSCs, hydroxyapatite, and tissue glue was developed. Animals from the treated group were implanted with biomaterial composed of hydroxyapatite and hMSCs, while animals in the control group received hydroxyapatite alone. When compared to controls, the group implanted with hMSCs showed a significantly higher ratio of new bone formation (p = 0.00174), as well as a significantly higher volume percentage of new immature bone (p = 0.00166). Our results proved a beneficial effect of hMSCs on temporal bone formation and provided a promising tool to improve the quality of life of patients after canal wall down mastoidectomy by hMSC implantation.
    WorkplaceInstitute of Experimental Medicine
    ContactLenka Koželská, lenka.kozelska@iem.cas.cz, Tel.: 241 062 218, 296 442 218
    Year of Publishing2017
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.